Production (Stage)
Inhibrx Biosciences, Inc.
INBX
$14.39
$0.473.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.97% | 48.86% | 15.30% | 3,344.63% | -98.71% |
| Total Depreciation and Amortization | 87.50% | 131.21% | 150.00% | 61.90% | 22.03% |
| Total Amortization of Deferred Charges | -57.09% | -100.00% | -100.00% | -14.42% | -- |
| Total Other Non-Cash Items | -57.97% | -49.85% | -50.36% | -25,647.47% | 34.05% |
| Change in Net Operating Assets | -53.81% | -99.99% | 185.28% | 526.22% | -0.85% |
| Cash from Operations | 43.07% | 23.06% | 44.18% | -44.82% | -134.05% |
| Capital Expenditure | 98.12% | 99.54% | 69.54% | -283.28% | -4,765.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 98.12% | 99.54% | 69.54% | -283.28% | -4,765.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -100.00% | 5,823.80% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -53.67% | -- |
| Cash from Financing | 157.80% | -100.00% | -100.00% | 217.45% | 43.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 351.26% | 26.37% | -121.08% | 37.25% | -- |